RN
Tonix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TNX-102 SL (TONMYA) | Acute Stress Disorder (ASD) | Phase 2 |
| TNX-102 SL | Multi-site pain associated with Long COVID (PASC) | Phase 2 (IND Active) |
| TNX-1500 | Organ Transplant Rejection / Autoimmune Disorders | Phase 1 |
| TNX-2900 | Prader-Willi Syndrome (PWS) | Phase 2 Ready |
| TNX-1700 | Gastric and Colorectal Cancer | Preclinical |
| TNX-801 | Prevention of Mpox or Smallpox | Preclinical |
| TNX-4200 | Not Specified (Targets CD45) | Preclinical |
Leadership Team at Tonix Pharmaceuticals
SL
Seth Lederman, MD
Co-Founder, Chief Executive Officer & Chairman
GS
Gregory Sullivan, MD
Chief Medical Officer
BS
Bradley Saenger, CPA
Chief Financial Officer
JE
Jessica Edgar Morris
Chief Operating Officer
SF
Siobhan Fogarty, BSc, MSc(QP)
Chief Technical Officer
SB
Sina Bavari, PhD
Executive Vice President, Infectious Disease Research and Development
BD
Bruce Daugherty, PhD, MBA
Executive Vice President, Research
TE
Thomas Englese, MBA
Executive Vice President, Commercial Operations
DR
Darryl Rideout, PhD
Executive Vice President, Experimental Chemistry
ZR
Zeil Rosenberg, MD, MPH
Executive Vice President, Medical